MedWellAI Inc. MWAI
- Market cap
- —
- P/E
- 0.0×
Follow MWAI
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | 176.25 | 13.75 | 1.13 | 1.00 | 4.00 | 1.88 | 0.94 | 0.75 | 0.20 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| — | 842.50 | 320.00 | 49.88 | 10.13 | 111.25 | 23.75 | 5.63 | 2.25 | 1.04 |
High Price
|
|||
| — | — | — | — | — | — | 1 | 1 | 1 | 1 |
Employees
|
|||
| — | — | 0 | 0 | 0 | 0 | 7 | 4 | 6 | 1 |
Revenue/Emp
|
|||
| — | — | 0 | 0 | 0 | 2 | 7 | 4 | 6 | 1 |
Revenue
|
|||
| — | — | 22.39% | (260.23%) | (119.37%) | 50.29% | 40.94% | 30.10% | 32.97% | 98.64% |
Gross Margin
|
|||
| (5) | (2) | (6) | (10) | (1) | (22) | (1) | (25) | (9) | (3) |
EBT
|
|||
| 0.00% | 0.00% | (1,820.33%) | (3,408.56%) | (238.18%) | (1,211.68%) | (8.63%) | (659.11%) | (156.10%) | (495.91%) |
EBT Margin
|
|||
| (5) | (2) | (6) | (10) | (1) | (22) | (1) | (25) | (9) | (3) |
Net Income
|
|||
| 0 | 1 | 0 | 1 | 1 | 1 | 2 | 4 | 3 | 0 |
Depreciation
|
|||
| 0.00 | 0.00 | 4.61 | 2.55 | 0.87 | 1.58 | 4.00 | 1.72 | 1.33 | 0.10 |
Revenue/Sh
|
|||
| (1,062.50) | (141.05) | (83.75) | (71.91) | (2.50) | (17.02) | — | (11.98) | (2.72) | (0.64) |
Earnings/Sh
|
|||
| (101.70) | (21.26) | (17.26) | (6.48) | (1.28) | (1.34) | 0.03 | (1.53) | (0.94) | (0.15) |
Cash Flow/Sh
|
|||
| 0.00 | 0.00 | (9.21) | (0.39) | 1.13 | 7.88 | 4.64 | 1.58 | 0.95 | 0.24 |
Capex/Sh
|
|||
| (101.70) | (21.26) | (26.46) | (6.87) | (0.15) | 6.54 | 4.67 | 0.06 | 0.01 | 0.09 |
Free CF/Sh
|
|||
| (315.34) | (4.00) | (32.10) | (9.96) | (0.21) | 11.21 | 8.99 | 1.61 | 0.06 | (0.41) |
Book Value/Sh
|
|||
| 0 | 0 | 0 | 0 | 1 | 1 | 2 | 2 | 4 | 6 |
Shares
|
|||
| — | — | 0.00 | 0.00 | 0.00 | 0.00 | 323.74 | 0.00 | 0.00 | 0.00 |
PE Ratio
|
|||
| — | — | 149.41 | 6.56 | 3.03 | 16.09 | 1.13 | 1.72 | 0.69 | 3.45 |
PS Ratio
|
|||
| — | — | 0.00 | 0.00 | 0.00 | 3.32 | 0.70 | 0.00 | 0.00 | 0.00 |
PB Ratio
|
|||
| — | — | 148.49 | 6.39 | 3.01 | 15.14 | 1.10 | 1.73 | 0.74 | 3.33 |
EV/Sales
|
|||
| — | — | (3.90) | (2.38) | (17.05) | 3.67 | 0.94 | 53.76 | 96.87 | 6.46 |
EV/FCF
|
|||
| 0 | 0 | (1) | (1) | (1) | (2) | 0 | (3) | (4) | (1) |
Op' Cash Flow
|
|||
| — | — | (1) | 0 | 1 | 9 | 8 | 4 | 4 | 1 |
Capex
|
|||
| 0 | 0 | (2) | (1) | 0 | 8 | 8 | 0 | 0 | 0 |
FCF
|
|||
| (1) | 0 | (3) | (2) | (1) | 2 | (1) | (2) | (1) | (3) |
Working Cap'
|
|||
| — | — | — | — | — | — | — | — | — | — | Total Debt | |||
| 0 | 0 | 0 | 0 | 0 | (2) | 0 | 0 | 0 | 0 |
Net Debt
|
|||
| (1) | 0 | (2) | (1) | 0 | 13 | 15 | 4 | 0 | (2) |
Sh' Equity
|
|||
| (12,210.19%) | (1,159.59%) | (990.85%) | (976.02%) | (129.81%) | (330.84%) | (7.53%) | (235.31%) | (228.08%) | (151.94%) |
ROA
|
|||
| 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (123.19%) | (3.02%) | (468.63%) | (2,810.70%) | 0.00% |
ROIC
|
|||
| 632.74% | 230.21% | 510.22% | 590.03% | 180.36% | (519.84%) | (11.42%) | (533.90%) | 548.93% | 69.86% |
ROE
|
|||
MedWellAI Inc. (MWAI) Latest News
6 May
MedWellAI Inc. (MWAI) reported Q3 revenues of $618,676 and provided a corporate update. Q3 revenue disclosure affects financial performance and investor sentiment moderately.
8 Apr
Apollo Biowellness, Inc. provides update on takeover by MedWellAI, Inc. Takeover update indicates major strategic acquisition enhancing MedWellAI's growth and market position.
23 Feb
MedWellAI Inc. (MWAI) reported strong Q2 revenues of $548,315 and provided full-year 2025 guidance exceeding $2,200,000. Strong Q2 revenues and 2025 guidance over $2.2M indicate significant positive impact on MWAI's financial performance and market sentiment.
10 Feb
MedWellAI Inc. has signed a Letter of Intent to establish America's first vertically integrated regenerative wellness eco-system. This initiative aims to combine various aspects of regenerative medicine and wellness services, enhancing patient care and accessibility. The company plans to integrate advanced technologies and treatment modalities to create a comprehensive platform for regenerative health solutions. The establishment of a vertically integrated eco-system is a significant strategic move that could enhance MedWellAI's market position and investor sentiment.
Apollo Biowellness has signed a Letter of Intent with MedWell AI, Inc. to collaborate on innovative healthcare solutions. This partnership aims to leverage MedWell AI's advanced artificial intelligence technologies to enhance Apollo's biowellness offerings. The agreement signifies a strategic move towards integrating AI into health and wellness services, potentially improving patient outcomes and operational efficiencies. The collaboration is expected to significantly enhance MedWell AI's product offerings and market positioning in the healthcare sector.
18 Aug
MedWellAI Inc. (MWAI) has partnered with Trump Mobile to engage BrighterMD in developing an AI-enhanced telemedicine platform targeting the $24.46 billion corporate wellness market. This collaboration aims to leverage advanced technology to improve healthcare delivery and access for corporate clients. The partnership represents a significant strategic move into a lucrative market, potentially enhancing MedWellAI's competitive positioning and financial performance.
24 Jun
MedWellAi, Inc., formerly known as Integrated Ventures, has completed a corporate rebranding to focus on AI-driven healthcare and wellness solutions. This transformation aims to enhance its market position and align with emerging trends in the healthcare sector, emphasizing the integration of artificial intelligence in its services. The rebranding and strategic shift towards AI-driven healthcare could significantly impact the company's future performance and market positioning.